First-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant lung cancer

A new drug, trastuzumab deruxtecan, slowed HER2-mutant lung cancer better than standard treatment in a large trial. It improved how long patients lived without the cancer getting worse.